Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Brentuximab vedotin after autoSCT in pediatric patients with R/R Hodgkin lymphoma

Lisa Roth • 20 Jun 2023
ICML 2023
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin

Lisa Roth, MD, Weill Cornell Medicine, New York, NY, discusses a multicenter retrospective study of pediatric patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who received brentuximab vedotin (BV) as maintenance therapy following autologous stem cell transplantation (autoSCT). Dr Roth shares that the treatment was well tolerated and safe, suggesting that this agent may be a promising option for pediatric patients. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lisa Roth

4:04
Molecular characterization of classical Hodgkin lymphoma
Lisa Roth • 20 Jun 2023
5:57
Treatment approaches, unmet needs, and ongoing research in younger patients with PMBCL
Lisa Roth • 20 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals